4//SEC Filing
Durham Mark Andrew 4
Accession 0000885590-10-000066
CIK 0000885590other
Filed
Dec 26, 7:00 PM ET
Accepted
Dec 27, 1:42 PM ET
Size
13.4 KB
Accession
0000885590-10-000066
Insider Transaction Report
Form 4
Durham Mark Andrew
SVP, Human Resources
Transactions
- Award
Restricted Share Units
2010-12-22+224→ 6,911 totalFrom: 2012-02-25Exp: 2012-02-25→ Common Stock, no par value (224 underlying) - Award
Restricted Share Units
2010-12-22+256→ 7,897 totalFrom: 2011-03-12Exp: 2011-03-12→ Common Stock, no par value (256 underlying) - Award
Restricted Share Units
2010-12-22+212→ 6,549 totalFrom: 2013-02-17Exp: 2013-02-17→ Common Stock, no par value (212 underlying) - Award
Restricted Share Units
2010-12-22+1,007→ 31,007 total→ Common Stock, no par value (1,007 underlying)
Footnotes (4)
- [F1]Each Restricted Share Unit (RSU) represents a contingent right to receive one share of Common Stock, no par value, of Valeant Pharmaceuticals International, Inc. (the "Common Stock").
- [F2]Represents dividend equivalents accrued on RSUs as a result of a dividend paid on the Common Stock on December 22, 2010.
- [F3]Each RSU represents a contingent right to receive between zero and three shares of Common Stock, subject to performance based vesting criteria. See note (4).
- [F4]The performance based RSUs will vest based on total shareholder return (TSR) between a price of $26.51 starting on September 28, 2010 and the average stock price for the prior 20 trading days as of three measurement dates: 25% would vest on June 28, 2013, 50% on September 28, 2013 and 25% on December 28, 2013. Unit vesting is contingent on TSR performance between 15% and 45% into between one and three shares of Common Stock, respectively, with early vesting possible at higher TSR levels.
Documents
Issuer
Valeant Pharmaceuticals International, Inc.
CIK 0000885590
Entity typeother
Related Parties
1- filerCIK 0001477126
Filing Metadata
- Form type
- 4
- Filed
- Dec 26, 7:00 PM ET
- Accepted
- Dec 27, 1:42 PM ET
- Size
- 13.4 KB